The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Regeneron (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Gary Edward Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Zivko Vranjes
No Relationships to Disclose
 
Tarek Meniawy
No Relationships to Disclose
 
Catherine M. Shannon
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Lilly; Merck sharp and Dohme; Roche
Speakers' Bureau - Amgen; AstraZeneca; Gilead Sciences; GlaxoSmithKline; merk sharp & Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Greenwich LifeSciences (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Stephanie V. Blank
Stock and Other Ownership Interests - Johnson & Johnson
Research Funding - Aravive (Inst); AstraZeneca (Inst); F. Hoffmann LaRoche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Cara Amanda Mathews
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Deciphera (Inst); EMD Serono (Inst); Laekna Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Syros Pharmaceuticals (Inst); Tesaro/GSK (Inst)
 
Jasmina Alidzanovic
No Relationships to Disclose
 
Rossitza Krasteva Ruseva
No Relationships to Disclose
 
Qing Shi
Employment - Zentalis
Stock and Other Ownership Interests - Zentalis
 
Olivier Harismendy
Employment - Zentalis
Stock and Other Ownership Interests - Zentalis
 
Ann M. Ptaszynski
Employment - Zentalis
Stock and Other Ownership Interests - Zentalis
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; Bayer; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; OncLive; Roche; Seagen; Targeted Oncology; Vaniam Group; Vincerx Pharma; Zentalis
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Mereo BioPharma (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Apeiron Biologics; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Lengo Therapeutics; Loxo; Menarini Group; OnCusp Therapeutics; PACT Pharmaceuticals; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Theratechnologies; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - AADi; AstraZeneca; Celsion; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; Iovance Biotherapeutics; Merck; Novocure; Seagen
Research Funding - GlaxoSmithKline (Inst); Merck (Inst)